Ophthotech Corp (NASDAQ:OPHT) insider David R. Guyer sold 16,520 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $3.19, for a total transaction of $52,698.80. Following the completion of the sale, the insider now directly owns 50,494 shares of the company’s stock, valued at approximately $161,075.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Ophthotech Corp (NASDAQ:OPHT) traded down $0.05 during trading on Thursday, reaching $3.25. 179,591 shares of the company’s stock traded hands, compared to its average volume of 558,700. Ophthotech Corp has a 12-month low of $2.24 and a 12-month high of $5.25. The company has a market capitalization of $117.49, a PE ratio of 2.08 and a beta of 1.58.

A number of institutional investors have recently modified their holdings of OPHT. First Manhattan Co. bought a new stake in Ophthotech in the third quarter worth about $1,201,000. Goldman Sachs Group Inc. raised its position in Ophthotech by 28.1% in the second quarter. Goldman Sachs Group Inc. now owns 652,992 shares of the biopharmaceutical company’s stock worth $1,672,000 after acquiring an additional 143,349 shares in the last quarter. Stonepine Capital Management LLC raised its position in Ophthotech by 1.7% in the second quarter. Stonepine Capital Management LLC now owns 3,576,189 shares of the biopharmaceutical company’s stock worth $9,155,000 after acquiring an additional 59,700 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in Ophthotech by 73.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 118,166 shares of the biopharmaceutical company’s stock worth $433,000 after acquiring an additional 49,928 shares in the last quarter. Finally, Federated Investors Inc. PA raised its position in Ophthotech by 102.3% in the second quarter. Federated Investors Inc. PA now owns 55,461 shares of the biopharmaceutical company’s stock worth $142,000 after acquiring an additional 28,040 shares in the last quarter. Hedge funds and other institutional investors own 62.48% of the company’s stock.

Several research firms recently weighed in on OPHT. TheStreet raised shares of Ophthotech from an “e+” rating to a “c” rating in a report on Thursday, November 30th. ValuEngine downgraded shares of Ophthotech from a “buy” rating to a “hold” rating in a report on Sunday. Stifel Nicolaus reaffirmed a “hold” rating and issued a $4.00 price objective on shares of Ophthotech in a report on Thursday, September 21st. Finally, Zacks Investment Research raised shares of Ophthotech from a “hold” rating to a “strong-buy” rating and set a $3.25 price objective for the company in a report on Monday, November 13th.

TRADEMARK VIOLATION NOTICE: “Ophthotech Corp (OPHT) Insider David R. Guyer Sells 16,520 Shares” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2018/01/04/ophthotech-corp-opht-insider-david-r-guyer-sells-16520-shares.html.

Ophthotech Company Profile

Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.

Insider Buying and Selling by Quarter for Ophthotech (NASDAQ:OPHT)

Receive News & Stock Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related stocks with our FREE daily email newsletter.